Is Your Paper Ready for NEJM? The Clinical Practice Test

The editorial standard at NEJM isn't scientific excellence alone. It's clinical significance: will physicians treat patients differently after reading this? The desk is where most papers end, and it's cleared based on clinical scope and significance, not methodological quality alone.

Three specific screening criteria:

Direct practice implications. NEJM wants studies where the results have immediate, actionable implications for clinical practice. A large RCT showing that drug A is superior to drug B for a common condition clears this bar. A biomarker study that might eventually lead to a new diagnostic test doesn't. The distinction is between "this changes practice now" and "this might change practice someday."

Patient-facing outcomes. NEJM strongly favors studies with hard clinical endpoints: mortality, major morbidity, hospitalization, disease-free survival. Surrogate endpoints (biomarker changes, imaging findings) are much harder to publish unless they're validated surrogates in a field where hard endpoints take decades to accrue.

Broad clinical relevance. Unlike The Lancet, which emphasizes global health and policy, NEJM focuses on clinical medicine practiced by physicians. The readership is primarily internists, cardiologists, oncologists, and other medical specialists. Your study needs to matter to this audience. Research relevant only to surgeons, pathologists, or basic scientists rarely clears the desk.

Editorial and review timing varies by manuscript, article type, reviewer availability, and revision history. A copied median does not make an unsuitable submission low-cost. Choose NEJM first only when the present paper supports the broad clinical-practice case; otherwise route directly to the audience that owns the decision.

Papers that clear NEJM's desk enter a distinctive dual review process:

Clinical peer review. External experts assess clinical significance, study design, and whether the conclusions are supported by the data. Reviewer number and timing can vary.

Statistical scrutiny. Expect the analytical methods, sample-size rationale, handling of missing data, multiplicity, and interpretation to be examined closely. The defensible preparation step is an independent statistical review before submission, not a claim about the journal's current staffing.

Common issues worth resolving before any external review include:

• Inappropriate handling of multiple primary endpoints without correction

• Sample size calculations that don't match the enrolled population

• Post hoc subgroup analyses presented as pre-specified

• Missing data handling that could bias results (e.g., last observation carried forward without sensitivity analyses)

• Overstated conclusions from non-inferiority or equivalence trials

If your statistician hasn't reviewed the manuscript before submission, fix that first. NEJM's statistical reviewers will find problems that clinical reviewers miss.

NEJM identifies reporting and submission requirements by article type. Missing elements can make a submission incomplete or unsuitable for review:

For randomized trials:

• CONSORT checklist (completed and submitted)

• Trial registration number (registered before enrollment)

• CONSORT flow diagram

• Data sharing statement

• Structured abstract of 250 words or fewer

For observational studies:

• STROBE checklist

• Clear statement of study design

• Handling of confounders

For all submissions:

• Conflict of interest disclosures for every author

• IRB/ethics committee approval documentation

• Complete methods section (NEJM does not accept abbreviated methods)

• Cover letter explaining why this paper is right for NEJM

The trial registration requirement deserves emphasis. NEJM was one of the first journals to mandate prospective trial registration, and they enforce it. If your trial wasn't registered before enrollment began, NEJM won't publish it. Retrospective registration doesn't count.

NEJM's cover letter expectations are more specific than most journals. The executive editor uses the cover letter to quickly assess fit, so yours should be direct and structured:

Paragraph one: the clinical question. What clinical question did you set out to answer? State it plainly. "We tested whether adding drug X to standard treatment improves survival in patients with advanced heart failure."

Paragraph two: the answer. What did you find? Effect size, confidence interval, primary outcome. No suspense, no buildup. Lead with the result.

Paragraph three: the practice implication. Why should a physician reading NEJM care? How would this change what they do in clinic? Be specific. "These results suggest that drug X should be added to guideline-recommended therapy for patients with NYHA class III-IV heart failure, potentially reducing mortality by 15%."

That's it. One page. Don't list your credentials. Don't explain why NEJM is a prestigious journal. Don't mention your institution's ranking. The executive editor doesn't have time, and none of it affects the editorial decision.

NEJM is the right journal when your paper meets all of these criteria:

You have a large, well-powered clinical trial or observational study. NEJM's bread and butter is randomized controlled trials and large cohort studies. Case reports, case series, and small pilot studies are rarely published as original research.

The primary outcome is a hard clinical endpoint. Mortality, hospitalization, major adverse events, disease-free survival. If your primary endpoint is a biomarker, an imaging finding, or a patient-reported outcome, the bar is much higher.

The finding changes clinical practice. Not "informs future research" or "suggests a new direction" but "changes what doctors do." If guidelines would be updated based on your results, NEJM wants to see it.

The disease or condition is common enough to matter broadly. NEJM's readership treats patients across all of internal medicine. A trial in a rare disease might be practice-changing for that disease but may not reach enough of NEJM's audience. Consider specialty journals for rare disease research unless the mechanism has implications beyond the specific condition.

A NEJM manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Basic science, even translational basic science. NEJM publishes clinical research. If your paper doesn't involve patients or populations, it belongs in Nature, Science, Cell, or a basic science journal.

Small, single-center studies. Unless the finding is so striking that the sample size doesn't matter (which is rare), NEJM expects multi-center studies or large single-center cohorts.

Studies with surrogate endpoints only. If you measured only biomarkers or imaging outcomes with no clinical endpoint data, NEJM will likely redirect you to a specialty journal.

Research without immediate practice implications. If the clinical application is three to five years away pending further trials, NEJM's editors will suggest you publish the current findings in a specialty journal and come back with the confirmatory trial.

A NEJM submission readiness check can help you evaluate whether your manuscript's clinical significance and statistical methodology meet NEJM's specific editorial standards before you submit.

Five evidence defects are worth testing before submission. They are manuscript checks derived from the journal's published remit and reporting expectations, not measured shares of private NEJM decisions.

Clinical trials that meet statistical significance without demonstrating clinical meaningfulness. The NEJM author guidelines emphasize direct clinical relevance. Report absolute effects, harms, and uncertainty so the reader can judge whether the result could change practice.

A hazard ratio of 0.96 with a p-value of 0.04 may be statistically significant in a large trial, but editors consistently apply the clinical meaningfulness test independently of the p-value. If a practicing clinician would not change treatment decisions based on the result, the paper does not clear the desk.

Observational studies with inadequately addressed confounding. When confounding is plausible, prespecified sensitivity analyses, negative controls, or other design-appropriate strategies can make the conclusion boundary inspectable. A long covariate list alone does not establish causality.

Standard multivariable adjustment is not considered sufficient when the exposure of interest is correlated with unmeasured behavioral or social factors. The journal's expectation is that authors anticipate this objection and address it directly in the design or analysis.

Basic science papers without a clear translational bridge to clinical medicine. A scientifically strong laboratory finding still needs a direct and evidenced connection to human disease or care to match a general medical journal's reader job.

The criterion is not whether the biology is interesting or the science is rigorous: it is whether a physician reading the paper would immediately understand why it matters for their patients. Findings that require several inferential steps before reaching clinical relevance do not clear the desk.

Meta-analyses with important heterogeneity and no explanation for it. Explore the sources of heterogeneity, predefine appropriate subgroup or sensitivity analyses, and keep the pooled conclusion within what the component evidence can support.

A meta-analysis that acknowledges substantial heterogeneity in a footnote and proceeds to present the pooled estimate as the primary finding is not treated as a rigorous synthesis: it is treated as a miscalculation of what can be concluded from the available data.

Case-level evidence routed to the wrong article type. Match the evidence to a current NEJM article category in the Author Center rather than forcing it into an Original Article structure.

An article-type mismatch cannot be repaired by cover-letter framing. Confirm the current category and requirements before upload.

Before submitting to New England Journal of Medicine, a New England Journal of Medicine manuscript fit check identifies whether your clinical meaningfulness evidence, confounding strategy, and article type meet NEJM's editorial bar before you commit to the submission.

Ready to submit if:

• You can pass every item on this checklist without qualifying language

• An experienced colleague in your field has read the manuscript and agrees it's competitive

• The data package is complete - no pending experiments or analyses

• You have identified why this journal specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped items on this checklist because you "plan to add them later"

• The methods section still has draft or incomplete protocol text

• Key figures are drafts rather than publication-quality

• You cannot articulate what distinguishes this paper from recent publications in this journal

For a manuscript-specific signal before you submit, run a free readiness scan.

Ready and well-matched are two different questions. See where NEJM lands among the venues that fit my abstract.

Use the NEJM journal profile to keep this readiness decision separate from general journal metrics.

NEJM says it seeks work that improves patient care and clinical practice or changes understanding of disease biology. A large sample, low p-value, or prominent disease area is not enough by itself. The manuscript should make the clinical decision and the evidence boundary visible together.

Ask a clinician outside the study area to name the decision, eligible patient, benefit, harm, and uncertainty after reading only the title, abstract, and first figure or table. Any missing answer is a first-screen problem. Repair the evidence-to-decision chain before adding stronger adjectives.

Evidence basis: This readiness screen was checked against the current NEJM Author Center, reporting expectations, and the cited metric source. It cannot predict acceptance or an editorial outcome. Hold the headline if it depends on a post hoc result, hold the practice claim if absolute effects or harms are unclear, and hold submission if registration, protocol, or analysis-plan evidence is incomplete. The table turns published expectations into a manuscript-level check without inventing an acceptance probability.

• Manusights local fit and process context from NEJM acceptance rate, NEJM review time, and NEJM cover letter.

• Clarivate Journal Citation Reports (2026 release for the 2025 Journal Impact Factor)

• Is Your Paper Ready for NEJM - Author Guidelines